Ken Griffin Painreform Ltd. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.43 - $0.69 $8,589 - $13,783
19,976 New
19,976 $10,000
Q3 2022

Nov 14, 2022
BUY
$0.62 - $0.96 $9,448 - $14,629
15,239 New
15,239 $11,000

About PAINREFORM LTD.

PRFX Quotes by TradingView
  • Ticker PRFX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 10,634,200
  • Market Cap $6.7M
  • Description
  • PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-oper...
More about PRFX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email